KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Operating Leases (2019 - 2025)

Historic Operating Leases for NovoCure (NVCR) over the last 7 years, with Q3 2025 value amounting to $42.7 million.

  • NovoCure's Operating Leases rose 10186.34% to $42.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.7 million, marking a year-over-year increase of 10186.34%. This contributed to the annual value of $20.0 million for FY2024, which is 2716.63% down from last year.
  • Latest data reveals that NovoCure reported Operating Leases of $42.7 million as of Q3 2025, which was up 10186.34% from $42.9 million recorded in Q2 2025.
  • Over the past 5 years, NovoCure's Operating Leases peaked at $42.9 million during Q2 2025, and registered a low of $11.5 million during Q3 2021.
  • Its 5-year average for Operating Leases is $21.8 million, with a median of $20.0 million in 2023.
  • As far as peak fluctuations go, NovoCure's Operating Leases crashed by 2716.63% in 2024, and later soared by 10186.34% in 2025.
  • NovoCure's Operating Leases (Quarter) stood at $13.0 million in 2021, then skyrocketed by 44.36% to $18.8 million in 2022, then soared by 46.15% to $27.4 million in 2023, then fell by 27.17% to $20.0 million in 2024, then surged by 113.72% to $42.7 million in 2025.
  • Its Operating Leases was $42.7 million in Q3 2025, compared to $42.9 million in Q2 2025 and $40.3 million in Q1 2025.